METHYCLOTHIAZIDE AND DESERPIDINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METHYCLOTHIAZIDE AND DESERPIDINE (METHYCLOTHIAZIDE AND DESERPIDINE).
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
| Metabolism | Methyclothiazide: not extensively metabolized; Deserpidine: extensively metabolized in the liver via CYP450 enzymes. |
| Excretion | Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%). |
| Half-life | Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing. |
| Protein binding | Methyclothiazide: 90-95% bound to albumin; Deserpidine: approximately 95% bound to plasma proteins (albumin and alpha-1 acid glycoprotein). |
| Volume of Distribution | Methyclothiazide: 0.3-0.6 L/kg, consistent with distribution in extracellular fluid; Deserpidine: 1-2 L/kg, indicating extensive tissue binding and distribution. |
| Bioavailability | Methyclothiazide: oral bioavailability 60-70% due to first-pass metabolism; Deserpidine: oral bioavailability 40-50% due to extensive first-pass hepatic metabolism. |
| Onset of Action | Methyclothiazide: diuresis within 2 hours after oral administration; Deserpidine: oral dose, antihypertensive effect occurs over several days to weeks. |
| Duration of Action | Methyclothiazide: diuretic effect lasts 12-24 hours; Deserpidine: antihypertensive effect persists for 1-2 weeks after discontinuation due to slow elimination. |
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in anuria. For GFR 30-60 mL/min: use with caution, monitor electrolytes. For GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment needed. Child-Pugh B: use with caution due to potential for hepatic encephalopathy. Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for use in children; safety and efficacy not established. |
| Geriatric use | Start with half the standard dose (0.5 tablet) once daily due to increased sensitivity to hypotension, electrolyte disturbances, and CNS effects. Titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for METHYCLOTHIAZIDE AND DESERPIDINE (METHYCLOTHIAZIDE AND DESERPIDINE).
| Breastfeeding | Methyclothiazide: Excreted in breast milk; may suppress lactation and cause neonatal electrolyte disturbances, jaundice, or thrombocytopenia. Deserpidine: Excreted in breast milk; may cause neonatal respiratory depression, bradycardia, and hypothermia. M/P ratio: not established for combination; use is contraindicated during breastfeeding. |
| Teratogenic Risk | Methyclothiazide: Thiazide diuretics cross the placenta and may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use in pregnancy, especially during the second and third trimesters, is associated with reduced placental perfusion and potential fetal harm; generally avoided for pregnancy-induced hypertension due to maternal hypovolemia risk. Deserpidine: Reserpine alkaloids cross the placenta and may increase respiratory secretions, nasal congestion, cyanosis, and hypothermia in neonates; also associated with increased risk of congenital malformations if used in first trimester. Contraindicated in pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to methyclothiazide, deserpidine, or sulfonamide-derived drugs","Anuria","History of mental depression","Active peptic ulcer","Ulcerative colitis","Electroconvulsive therapy"]
| Precautions | ["Possible exacerbation or activation of systemic lupus erythematosus","Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia)","Orthostatic hypotension","Depression (due to deserpidine component)","Potential for mental depression, especially in patients with history of depression"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (especially potassium and sodium), renal function, and uric acid levels. Observe neonate for jaundice, thrombocytopenia, electrolyte disturbances, and respiratory depression. Consider placental perfusion assessment with Doppler if used in pregnancy. |
| Fertility Effects | Thiazide diuretics may rarely cause erectile dysfunction; deserpidine may impair fertility via neuroendocrine effects. Limited data; no significant female fertility issues reported. |